Skip to content

Just another WordPress site

Monthly Archives: February 2017

Redirecting N-Acetylaspartate Metabolism in the Central Nervous System Normalizes Myelination and Rescues Canavan Disease

Posted byJulianne TwiningFebruary 9, 2017February 11, 2019Posted inUncategorizedLeave a comment on Redirecting N-Acetylaspartate Metabolism in the Central Nervous System Normalizes Myelination and Rescues Canavan Disease

Search for:

Recent Posts

BridgeBio Pharma Announces Pricing of Its Initial Public Offering
BridgeBio Pharma Announces Filing of Registration Statement for Proposed Initial Public Offering
Eidos Therapeutics Initiates Attribute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint
Phoenix Tissue Repair Doses First Patient in Phase 1/2 Clinical Trial of PTR-01 (BBP-589) for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
BridgeBio Pharma Closes $299.2 Million Financing Round to Support Its Efforts to Target Genetic Disease at the Source

Recent Comments

Archives

June 2019
May 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
August 2018
June 2018
May 2018
April 2018
March 2018
January 2018
November 2017
October 2017
September 2017
July 2017
April 2017
February 2017
January 2017
December 2016

Categories

investor
partner
Uncategorized

Meta

Log in
Entries RSS
Comments RSS
WordPress.org

bridgebiowp, Proudly powered by WordPress.